Skip to main content

Table 1 Characteristics of enrolled individuals

From: Distinct tumour antigen-specific T-cell immune response profiles at different hepatocellular carcinoma stages

 

controls

HCC

HC (n = 10)

CHB (n = 15)

LC (n = 15)

0 + A (n = 25)

B + C (n = 33)

Gender (Male/Female)

7/3

9/6

11/4

19/6

30/3

Age

51.39 ± 1.49

49.56 ± 12

48.33 ± 9.11

52.53 ± 5.80

51.82 ± 11.82

HBV/HCV/other

/

/

/

21/3/1

29/3/1

HBV-DNA (positive/negative/ND)

/

8/7/0

5/10/0

4/6/15b

9/10/14b

Tumour number (solitary/multiple)

/

/

/

21/4

13/20

Tumour volume (S/H) c

/

/

/

19/6

10/23

VI/M (no/yes)

/

/

/

25/0

18/15

Differentiation (well/moderate/poor/ND)

/

/

/

2/2/3/18

1/6/4/22

Curative therapy (no/yes)

/

/

/

3/22

17/16

Recurrence at 1-year (no/yes)

/

/

/

11/11

5/11

WBC (109/L)

5.22 ± 1.26

6.18 ± 2.29

4.83 ± 1.88

4.34 ± 1.63b

5.26 ± 2.39

HGB (g/L)

141.29 ± 11.48

147.17 ± 21.97

154.33 ± 18.49

141.42 ± 19.39

141.16 ± 19.67

PLT (109/L)

221.43 ± 72.04

199.17 ± 70.41

128.42 ± 73.48a, b

103.88 ± 48.64a, b

154.66 ± 90.71

ALT (U/L)

N.D.

35.13 ± 26.50

42.29 ± 43.37

32.17 ± 23.26

48.88 ± 38.08

AST (U/L)

N.D.

41.07 ± 47.89

43 ± 31.51

36.30 ± 17.38

42.92 ± 23.08b

TBiL (μmmol/L)

N.D.

16.49 ± 6.08

33.16 ± 23b

21.02 ± 12.41

17.90 ± 9.15

ALB (g/L)

N.D.

44.78 ± 3.31

42.34 ± 5.94

38.32 ± 5.58b

39.82 ± 4.91b

PT (s)

N.D.

N.D.

15.27 ± 4.65

13.10 ± 1.61

12.37 ± 1.26

PTA (%)

N.D.

N.D.

70.33 ± 17.88

80.17 ± 13.54

86.97 ± 11.53

AFP (ng/mL)

/

/

/

169.21 ± 298.08

8729.39 ± 31,115.08

PIVKA-II (mAU/mL)

/

/

/

355.73 ± 603.26

3574.86 ± 7725.33

  1. Abbreviations: HC, healthy control. CHB, chronic hepatitis B. LC, liver cirrhosis derived from CHB. HBV, hepatitis B virus; VI/M, vascular invasion/metastasis; ND, not determined. WBC, White Blood Cell. HGB, hemoglobin. PLT, platelet. ALT, alanine aminotransferase. AST, aspartate aminotransferase. TBil, total bilirubin. ALB, albumin. PT, prothrombin time. PTA, prothrombin activity. AFP, alpha-fetoprotein. PIVKA-II, protein induced by vitamin K absence or antagonist-II
  2. Data were expressed as mean ± SD. a: p < 0.05 compared with the HC group. b: p < 0.05 compared with the CHB group. c: we divided the patients into two groups according to the tumour volume, S indicates tumour volume < 15 cm3 and H means the tumour volume > 15 cm3